Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Management Group Inc.

Private Management Group Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 211,383 shares of the biopharmaceutical company's stock after selling 206,514 shares during the period. Private Management Group Inc.'s holdings in Gilead Sciences were worth $19,525,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $25,000. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares during the last quarter. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $29,000. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded down $2.00 during trading hours on Friday, hitting $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $93.04 and a 200-day moving average of $86.76. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The stock has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Oppenheimer lifted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Daiwa America upgraded shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Piper Sandler boosted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Barclays lifted their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.39.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares of the company's stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 over the last quarter. Insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.